

## Department of Planning and Budget 2013 Fiscal Impact Statement

**1. Bill Number:** SB 1250

<b>House of Origin</b>	<input checked="" type="checkbox"/> Introduced	<input type="checkbox"/> Substitute	<input type="checkbox"/> Engrossed
<b>Second House</b>	<input type="checkbox"/> In Committee	<input type="checkbox"/> Substitute	<input type="checkbox"/> Enrolled

**2. Patron:** Puckett, Phillip P.

**3. Committee:** Education and Health

**4. Title:** Prescription Monitoring Program; Board of Pharmacy to identify "drugs of concern"

**5. Summary:** The proposed legislation authorizes the Board of Pharmacy to identify “drugs of concern” and requires prescribers to report prescription drugs of concern to the Prescription Monitoring Program.

**6. Budget Amendment Necessary:** No. There is no clear estimate as to the additional expenditure required by this legislation, however additional nongeneral fund appropriation can be provided administratively once such spending needs are determined.

**7. Fiscal Impact Cannot Be Determined:** See Item 8

**8. Fiscal Implications:** The proposal would require the promulgation of regulations by the Board of Pharmacy to identify a “drug of concern” as a covered substance thereby making it subject to reporting to the Prescription Monitoring Program (PMP). Since the “drug of concern” would not be a schedule II – IV drug and routinely reported by dispensers, there would be a cost relating to communicating such a requirement for reporting to pharmacies and notification to prescribers that the “drug of concern” would be included in the PMP. There would also be some additional cost for alteration of the database of the PMP to capture that information. Costs to PMP and to the Board of Pharmacy would depend on how often a “drug of concern” was added and the method used for communicating with prescribers and dispensers.

Since it is unknown as to how many “drugs of concern” would be identified; the fiscal impact on the agency cannot be determined. PMP is funded with federal and endowment funds without any support from regulatory fee revenue. It is estimated that there are sufficient funds to cover any PMP related costs associated with this bill. It is further estimated that the Board of Pharmacy would have revenue sufficient to cover any increased costs.

**9. Specific Agency or Political Subdivisions Affected:** Department of Health Professions

**10. Technical Amendment Necessary:** No

**11. Other Comments:** None

**Date:** 1/17/13

**Document:** G:\2013 Fiscal Year\2013 GA Session\EFIS\SB1250.docx